SONN

Sonnet BioTherapeutics

Delisted

SONN was delisted on the 2nd of December, 2025.

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 100%
Negative

Neutral
GlobeNewsWire
yesterday
Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Hyperliquid Strategies Common Stock Expected to Begin Trading on Nasdaq on Wednesday, December 3 Under the Ticker “PURR” Hyperliquid Strategies Common Stock Expected to Begin Trading on Nasdaq on Wednesday, December 3 Under the Ticker “PURR”
Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Neutral
GlobeNewsWire
16 days ago
Sonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special Meeting
PRINCETON, N.J., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc., (NASDAQ: SONN) (“Sonnet” or the “Company”) today announced that it has adjourned its special meeting of stockholders (the “Special Meeting”) in order to provide stockholders additional time within which to vote on its proposed business combination (the “Business Combination”) with Hyperliquid Strategies Inc (“HSI”) and Rorschach I LLC (“Rorschach”), and the other proposals to be considered at the special meeting.
Sonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special Meeting
Neutral
GlobeNewsWire
1 month ago
Evaluation of SON-1010 Using a Patient-Derived Tumoroid Platform to Support an Ongoing Phase 1 Study in Patients with Sarcoma
HOUSTON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) is collaborating with Spanios on a non-clinical study using New Alternate Methodologies (NAM)-based patient-derived tumoroid (PDT) platforms that emulate the tumor microenvironment (TME) ex vivo to evaluate the effect of SON-1010 (IL-12-FHAB) in soft tissue sarcoma. The study aims to speed up the development of treatments for patients with rare and difficult-to-treat cancers.
Evaluation of SON-1010 Using a Patient-Derived Tumoroid Platform to Support an Ongoing Phase 1 Study in Patients with Sarcoma
Neutral
GlobeNewsWire
2 months ago
Sonnet to Present at the MedInvest Biotech & Pharma Conference
PRINCETON, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME), today announced that Raghu Rao, Interim Chief Executive Officer of Sonnet, will present on Thursday, September 25, 2025 at 9:40 AM PT at the MedInvest Biotech & Pharma Conference being held in Palo Alto, California.
Sonnet to Present at the MedInvest Biotech & Pharma Conference
Neutral
GlobeNewsWire
3 months ago
Sonnet Releases Virtual Investor "What This Means" Segment
- Dr. Richard Kenney, Chief Medical Officer of Sonnet, discusses the recently announced expansion of its clinical study of patients with platinum-resistant ovarian cancer (PROC) (SB221)
Sonnet Releases Virtual Investor "What This Means" Segment
Neutral
GlobeNewsWire
4 months ago
Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer
Sonnet's lead product, SON-1010 (IL12-F H AB), is being evaluated in combination with atezolizumab (Tecentriq ® ) in patients with advanced platinum-resistant ovarian cancer (PROC) (SB221)
Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer
Neutral
GlobeNewsWire
4 months ago
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Sonnet BioTherapeutics, Inc. (NASDAQ: SONN)
NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Sonnet BioTherapeutics, Inc. (NASDAQ: SONN ) related to its merger with Rorschach I LLC. Upon completion of the proposed transaction, Sonnet shareholders will own approximately 1% of the combined company. Is it a fair deal?
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Sonnet BioTherapeutics, Inc. (NASDAQ: SONN)
Positive
Benzinga
4 months ago
Why Is Sonnet BioTherapeutics Stock Trading Higher On Monday?
Sonnet BioTherapeutics Inc. SONN stock surged Monday amid high trading volume following news of a transformative business combination with Rorschach I, backed by Atlas Merchant Capital and Paradigm.
Why Is Sonnet BioTherapeutics Stock Trading Higher On Monday?
Positive
Finbold
4 months ago
This stock rockets 260% after $900 million mega crypto deal
Shares of Sonnet BioTherapeutics (NASDAQ: SONN) soared in pre-market trading on Monday after the company announced a $888 million business combination to pivot into the cryptocurrency sector.
This stock rockets 260% after $900 million mega crypto deal
Neutral
Business Wire
4 months ago
SONN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Sonnet BioTherapeutics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Sonnet BioTherapeutics, Inc. (NASDAQ: SONN) and Rorschach I LLC is fair to Sonnet shareholders. Upon completion of the proposed transaction, Sonnet shareholders will own approximately 1% of the combined company. Halper Sadeh encourages Sonnet shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sa.
SONN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Sonnet BioTherapeutics, Inc. Is Fair to Shareholders